HCG Manavata Cancer Centre, Nashik
19 years of experience
MBBS, MS, MRCS (Edin), DNB (General Surgary) BSS, MNAMS
Dr Raj has received his Surgical Oncology training at the Prestigious Tata Memorial Hospital, Mumbai followed by MRCS at the Royal College of Surgeons, Edinburgh. He started his Surgical Oncology practise in the year 2000 at Nashik and established Curie Manavata Cancer Centre in 2007. He has a vast experience of 19 years and has performed more than 42,000+ cancer surgeries. He has been involved in more than 200 phase 1-3 and investigator initiated clinical trials. He has multiple authorships, International and National publications to his credit. His main area of interest is in Breast and Thoracic Surgical Oncology. Dr Raj is a professor for DNB Superspecialty Surgical Oncology for Delhi National Board & professor for Breast Surgery at the Maharashtra University of Health Sciences (MUHS). A competent professional with nearly 19 years of experience in the field of Oncology, Dr Raj Vasant Nagarkar has been serving the entire Maharashtra Region in all avenues of Oncology. Dr Raj Nagarkar before being Surgical Oncologist was an engineering student; there came a turn in his life and career when his grandmother was detected with Cervical Cancer, it is then where he made a choice of being oncologist and went on to pursue Medical as his profession. His attitude of achieving perfection and Commitment to give the best to the society has resulted to the craftsmanship of HCG Manavata Cancer Centre, Nashik. It was initially started as a state-of-the-art technologically driven 72 bedded one-stop comprehensive cancer centre situated at Nashik, which has now progressed to a 275-bedded largest pvt. Cancer centre in India. It is the first NABH accredited dedicated cancer care hospital in Maharashtra and has 450+ well skilled and compassionate hands to care for the patients. The quality of medical care provided at the hospital under the guidance of Dr Raj Nagarkar, has been recognized and honored by many national & international awards including the ТInternational Health Care Award 2016У in the category of Most promising Cancer Centre in Maharashtra. Dr Nagarkar has examined and treated more than 55000 cancer patients and performed more than 29000 Major & supra-major cancer surgeries, 750+ Childhood cancer patients and conduct more than 200 multinational clinical trials in Oncology. Dr Nagarkar has been awarded various authorships for the trials conducted. Dr Raj Nagarkar has started ТHCG Manavata Jan Jagruti AbhyaanУ and has been instrumental in creating awareness among the masses regarding tobacco hazards, early symptoms of cancer, importance of screening & completing scientific treatments in more than 1400 screening camps and lectures delivered benefitting more than 22,000 screened individuals in and around the entire north Maharashtra and now is spreading its services to entire Maharashtra.
MBBS from Jawaharlal Nehru Medical College , Belgaum; 1996 MS from Tata Memorial Hospital, Mumbai; 2000 BSS from Royal College of Surgeons, Edinburgh; 2000 DNB from Ministry of Health, New Delhi; 2000 Membership of Royal college of Surgeons, Edinburgh (MRCSEd) Royal College of Surgeons, Edinburgh; 2000 Membership of National Academy of Medical Sciences (MNAMS) Ministry of Health, New Delhi; 2004 ICH-GCP Training in Various Investigators Meetings
Consultant Surgical Oncologist, HCG Manavata Cancer Centre, Nashik
Maharashtra Oncology Group
Breast Cancer, Thoracic Cancer.
Palwe, Vijay & Nagarkar, Rajnish. (2013). TACE plus sorafenib for the treatment of advanced hepatocellular carcinoma.. Journal of Clinical Oncology. 31. e15178-e15178. https://doi.org/10.1200/jco.2013.31.15_suppl.e15178 Poveda, Andres & Oza, Amit & Fabbro, Michel & Redondo, AndrЋs & Bamias, Aristotle & Covens, Al & Romero, Ignacio & Bae, Duk-Soo & Censi, Andrea & Nagarkar, Rajnish & Richardson, Gary & Gallardo-Rinc—n, Dolores & Rasmussen, Erik & Rossi, John & Bass, Michael & Warner, Douglas & Monk, Bradley. (2014). Expression of angiopoietin (Ang) pathway markers and their relationship to progression-free survival (PFS) in TRINOVA-1.. Journal of Clinical Oncology. 32. 5542-5542. https://doi.org/10.1200/jco.2014.32.15_suppl.5542 Ahmad, Ateeq & Sheikh, Saifuddin & Mehta, Ajay & Nagarkar, Rajnish & Srinivasan, Krishnan & Majumdar, Anup & Mukherjee, Kalyan & Singh, Jitendra & Shrivastav, SP & Thungappa, Satheesh & Maksud, Tanveer & Pawar, Suraj & Sonawane, Satish & Kamat, Satish & Sharma, Manish & Rane, R. & Ahmad, Imran. (2014). Cremophor EL-free formulation of paclitaxel: A randomized, multicenter, safety, and efficacy study of nanosomal paclitaxel lipid suspension (NPLS) versus paclitaxel in women with metastatic breast cancer (MBC).. Journal of Clinical Oncology. 32. 573-573. https://doi.org/10.1200/jco.2014.32.15_suppl.573 Im, Young-Hyuck & Uslu, RџЌhan & Lee, Keun Seok & Nagarkar, Rajnish & Sohn, Joohyuk & Sevinc, Alper & Altundag, Kadri & Chang, Yuan-Ching & Abdel-Razeq, Hikmat & Im, Seock-Ah & Jeong, Joon & Park, Ho & Arpornwirat, Wichit & Bastick, Patricia & Le, Tuan & Arikan, Ozlem & Xue, Hong-Ling & Canatar, Aycin & Valenti, Roberta & Kim, Sung-Bae. (2015). Clinical effectiveness of Everolimus and Exemestane in advanced breast cancer patients from Asia and Africa: First efficacy and updated safety results from the phase IIIb EVEREXES study.. Journal of Clinical Oncology. 33. e11579-e11579. https://doi.org/10.1200/jco.2015.33.15_suppl.e11579 Soulieres, Denis & Faivre, Sandrine & Mesia, R. & Remenar, Eva & Li, Shau-Hsuan & Karpenko, Andrey & Dechaphunkul, Arunee & Kiss, Laura & Lin, Jin-Ching & Nagarkar, Rajnish & Tamas, Laszlo & Kim, Sung-Bae & Erf‡n, Jozsef & Turri, Sabine & Dey, Debarshi & Chakravartty, Arunava & Aimone, Paola & Massacesi, Cristian & Licitra, Lisa. (2016). BERIL-1: A phase II, placebo-controlled study of buparlisib (BKM120) plus paclitaxel in patients with platinum-pretreated recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).. Journal of Clinical Oncology. 34. 6008-6008. https://doi.org/10.1200/JCO.2016.34.15_suppl.6008 Viswabandya, Auro & Mukhopadhyay, Asis & Shah, Sandip & Nagarkar, Rajnish & Batra, Sonica & Lopez-Lazaro, Luis & Kankanwadi, Suresh & Srivastava, Alok. (2016). Comparison of Pharmacokinetics and Pharmacodynamics of Two Anti-CD20 Monoclonal Antibodies (Candidate Biosimilar DRL-Rituximab and Innovator Reference Product Rituximab (MabtheraЁ) in a Randomised, Multi-Centre, Double-Blind, Parallel Group Study of CHOP with Rituximab Chemotherapy in Patients with CD20-Positive Diffuse Large B-Cell Lymphoma. Blood. 128. 5391-5391. https://doi.org/10.1182/blood.V128.22.5391.5391 Shah, Sandip & Viswabandya, Auro & Mukhopadhyay, Asis & Nagarkar, Rajnish & Batra, Sonica & Lopez-Lazaro, Luis & Kankanwadi, Suresh & Srivastava, Alok. (2017). Comparative double-blind randomized trial of 2 rituximab products in patients with CD20+ diffuse large B-cell lymphoma (DLBCL).. Journal of Clinical Oncology. 35. 7550-7550. https://doi.org/10.1200/JCO.2017.35.15_suppl.755 Viswabandya, Auro & Shah, Sandip & Mukhopadhyay, Asis & Nagarkar, Rajnish & Batra, Sonica & Lopez-Lazaro, Luis & Kankanwadi, Suresh & Srivastava, Alok. (2019). Randomized, Double-Blind, Pharmacokinetic Equivalence Trial Comparing DRL-Rituximab With MabThera in Patients With Diffuse Large B-Cell Lymphoma. Journal of Global Oncology. 5. 1-13. https://doi.org/10.1200/JGO.19.00248 Dr S R Shinde Memorial cancer Workshop; 2001. Attended by 150 consultants from North Maharashtra Cancer 2003; Attended by 265 consultants from North Maharashtra Maharashtra Breast Cancer Conference; 2008. Two day conference with operative workshop covering various aspects of breast cancer. Attended by 72 oncologists from Maharashtra & Goa
Breast Cancer, Thoracic Cancer.